AR and melanoma: For further mechanistic insights, we conducted ChIP-seq analysis using anti-AR antibodies on A375 melanoma cells with and without AR overexpression and compared the ChIP-seq profiles with those of AR in the same cells after early treatment with BRAFi (DAB).